Novartis Q1 EPS and Revenue Miss Estimates, Maintains 2026 Growth Outlook
Novartis reported Q1 2026 earnings and revenue that fell below estimates, despite maintaining its 2026 growth outlook. The company faces challenges from patent cliffs but continues to promise growth through strategic initiatives. The results led to a rating downgrade from some analysts.
Tickers: $NVS
Topics: business strategy earnings preview Novartis patent cliffs product expansion